

Giuseppe Milone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6147489/publications.pdf>

Version: 2024-02-01

150
papers

4,457
citations

109321

35
h-index

114465

63
g-index

152
all docs

152
docs citations

152
times ranked

5411
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 267-270.	2.3	5
2	Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 253.	2.4	10
3	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. <i>Journal of Clinical Medicine</i> , 2022, 11, 623.	2.4	20
4	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 942.	2.4	5
5	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	1.2	4
6	Chemotherapy-based versus chemotherapy-free stem cell mobilization (Â± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1876-1887.	2.4	8
7	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. <i>Annals of Hematology</i> , 2021, 100, 1743-1753.	1.8	7
8	Low content of clonogenic progenitors on day+18 is associated with acute graft-versus-host disease and predicts transplant-related mortality. <i>Experimental Hematology</i> , 2021, 95, 58-67.e4.	0.4	0
9	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	2.4	18
10	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
11	Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group. <i>Transplantation</i> , 2021, 105, 686-694.	1.0	6
12	Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. <i>Blood</i> , 2021, 138, 2849-2849.	1.4	0
13	Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. <i>Blood</i> , 2021, 138, 475-475.	1.4	4
14	Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost. <i>Leukemia Research Reports</i> , 2020, 14, 100227.	0.4	1
15	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	2.4	6
16	On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBLO6877). <i>Blood</i> , 2020, 136, 13-14.	1.4	0
17	Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy. <i>Chemotherapy</i> , 2019, 64, 110-114.	1.6	1
18	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	1.3	9

#	ARTICLE	IF	CITATIONS
19	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , 2019, 6, e89-e99.	4.6	47
20	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1387-1394.	2.0	2
21	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 932-940.	2.0	25
22	B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 <i>BCR-ABL</i> Transcripts: A Case Report. <i>Anticancer Research</i> , 2019, 39, 431-435.	1.1	13
23	Preliminary Results of a Combined Score Based on sIL2-R α and TIM-3 Levels Assayed Early After Hematopoietic Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 3158.	4.8	7
24	Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification. <i>Blood</i> , 2019, 134, 3271-3271.	1.4	3
25	Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens. <i>Blood</i> , 2019, 134, 1974-1974.	1.4	0
26	Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study. <i>Bone Marrow Transplantation</i> , 2018, 53, 291-299.	2.4	4
27	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	2.4	28
28	Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 42-48.	1.3	12
29	â€œReal-lifeâ€™ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018, 53, 58-63.	2.4	7
30	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph α ™+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. <i>Chemotherapy</i> , 2018, 63, 220-224.	1.6	19
31	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the <sc>EBMT</sc> Lymphoma Working Party and <sc>FIL</sc>â€œ<sc>GITMO</sc>. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.5	19
32	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. <i>Blood</i> , 2018, 132, 4642-4642.	1.4	0
33	ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3381-3381.	1.4	0
34	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 609-609.	1.4	0
35	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
36	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1549-1554.	2.0	25

#	ARTICLE	IF	CITATIONS
37	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2017, 52, 372-380.	2.4	53
38	Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica, 2017, 102, 2125-2133.	3.5	27
39	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	5.8	103
40	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before HLA-replete haploidentical transplantation. Transfusion, 2016, 56, 1096-1100.	1.6	11
41	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplantation, 2016, 51, 1032-1040.	2.4	26
42	Antitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinase. Anti-Cancer Drugs, 2016, 27, 609-619.	1.4	20
43	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biology of Blood and Marrow Transplantation, 2016, 22, 744-751.	2.0	41
44	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2016, 374, 43-53.	27.0	436
45	Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis. Blood, 2016, 128, 3475-3475.	1.4	1
46	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). Blood, 2016, 128, 3473-3473.	1.4	0
47	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell'Adulto Multiple Myeloma Working Party study. Stem Cell Research and Therapy, 2015, 6, 64.	5.5	25
48	Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplantation, 2015, 50, 790-794.	2.4	15
49	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplantation, 2015, 50, 505-510.	2.4	16
50	Quality assessment of autologous haematopoietic blood progenitor cell grafting. Annals of Hematology, 2015, 94, 705-706.	1.8	0
51	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 2015, 94, 1347-1356.	1.8	31
52	Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment. Experimental Hematology, 2015, 43, 430-438.e1.	0.4	10
53	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 1525-1536.	10.7	143
54	Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Annals of Hematology, 2015, 94, 1875-1883.	1.8	47

#	ARTICLE	IF	CITATIONS
55	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	2.4	142
56	Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma. <i>Blood</i> , 2015, 126, 4305-4305.	1.4	0
57	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	1.6	39
58	Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. <i>Mycoses</i> , 2014, 57, 342-350.	4.0	43
59	A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. <i>Bone Marrow Transplantation</i> , 2014, 49, 376-381.	2.4	8
60	Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. <i>Bone Marrow Transplantation</i> , 2014, 49, 1193-1197.	2.4	3
61	Algorithms for early identification of poor mobilization and for on-demand use of plerixafor in patients mobilized by chemotherapy and granulocyte-colony stimulating factor. <i>Leukemia and Lymphoma</i> , 2014, 55, 725-726.	1.3	1
62	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
63	Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. <i>British Journal of Haematology</i> , 2014, 164, 113-123.	2.5	55
64	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	1.6	55
65	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
66	Gvhd-Associated Early Impairment of Marrow Function Is Frequent after Allogeneic Transplantation and Is a Sensitive Biomarker for Prediction of Treatment Related Mortality and of Overall Survival. <i>Blood</i> , 2014, 124, 1160-1160.	1.4	1
67	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopoietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). <i>Blood</i> , 2014, 124, 37-37.	1.4	9
68	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 727-727.	1.4	1
69	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	1.4	2
70	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	4.1	61
71	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SidEM) survey. <i>Transfusion and Apheresis Science</i> , 2013, 49, 615-622.	1.0	8
72	In AML patients treated by allogeneic hematopoietic transplantation, CD34+ supermobilization is a negative prognostic factor. <i>Leukemia Research</i> , 2013, 37, 853-854.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1670-1676.	2.0	26
74	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
75	Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013, 121, 440-446.	1.4	143
76	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	1.4	171
77	Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. <i>Haematologica</i> , 2013, 98, 172-178.	3.5	50
78	Palifermin in high dose chemotherapy and autologous stem cell transplantation reduces infection rate. <i>Drugs and Cell Therapies in Hematology</i> , 2013, 2, 133.	0.1	1
79	Palifermin in high dose chemotherapy and autologous stem cell transplantation reduces infection rate. <i>Drugs and Cell Therapies in Hematology</i> , 2013, 2, .	0.1	0
80	Plerixafor On Demand Associated With Chemotherapy and G-CSF: Interim Analysis Of a Prospective Study Shows Significant Improvement In PBSC Mobilization and Harvest With No Increase In Costs. <i>Blood</i> , 2013, 122, 4509-4509.	1.4	0
81	Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. <i>Blood Transfusion</i> , 2013, 11, 94-101.	0.4	13
82	Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2012, 47, 24-32.	2.4	8
83	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. <i>Bone Marrow Transplantation</i> , 2012, 47, 831-837.	2.4	31
84	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1449-1462.	3.1	18
85	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2012, 26, 1091-1097.	7.2	85
86	Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2475-2482.	1.6	185
87	Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1093-7.	2.3	4
88	Plerixafor Added to Chemotherapy Plus G-CSF Is Safe And Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 241-249.	2.0	69
89	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	1.8	74
90	Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: Association with CD34+ mobilization and with disease-free survival. <i>Experimental Hematology</i> , 2012, 40, 35-47.e2.	0.4	6

#	ARTICLE	IF	CITATIONS
91	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. <i>Blood</i> , 2012, 120, 1984-1984.	1.4	1
92	CD34+ mobilization and pbpc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. <i>Drugs and Cell Therapies in Hematology</i> , 2012, 1, 91.	0.1	1
93	CD34+ mobilization and pbpc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. <i>Drugs and Cell Therapies in Hematology</i> , 2012, 1, .	0.1	0
94	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. <i>Blood</i> , 2012, 120, 4094-4094.	1.4	0
95	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	7.2	51
96	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. <i>Human Pathology</i> , 2011, 42, 254-268.	2.0	17
97	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. <i>Leukemia Research</i> , 2011, 35, 899-903.	0.8	20
98	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	1.6	171
99	Inadvertent transplantation of haematopoietic stem cells carrying constitutional Robertsonian translocation from an apparently normal donor to an AML patient: a case report. <i>Bone Marrow Transplantation</i> , 2011, 46, 1278-1279.	2.4	6
100	AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. <i>Bone Marrow Transplantation</i> , 2011, 46, 314-316.	2.4	14
101	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. <i>Blood</i> , 2011, 118, 2009-2009.	1.4	1
102	Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC): A Retrospective Study From the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 3077-3077.	1.4	1
103	The Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. <i>Blood</i> , 2011, 118, 4139-4139.	1.4	0
104	Palifermin In High Dose Chemotherapy and Autologous Stem Cell Transplantation: Reduction of Infections and of Resources Utilization with No Increase in Overall Cost. <i>Blood</i> , 2011, 118, 4568-4568.	1.4	0
105	Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. <i>BMC Cancer</i> , 2010, 10, 377.	2.6	26
106	Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. <i>Bone Marrow Transplantation</i> , 2010, 45, 385-391.	2.4	53
107	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	1.4	151
108	Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. <i>Leukemia</i> , 2009, 23, 199-203.	7.2	7

#	ARTICLE	IF	CITATIONS
109	Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.. Blood, 2009, 114, 52-52.	1.4	15
110	Haemato-oncology and burnout: an Italian survey. British Journal of Cancer, 2008, 98, 1046-1052.	6.4	67
111	A Prospective Study on the Feasibility of Related and Unrelated Donor Search and Hematopoietic Cell Transplantation for Adults with Acute Leukemia at 31 European Transplant Centers. Blood, 2008, 112, 2385-2385.	1.4	0
112	Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m2plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients. Leukemia and Lymphoma, 2007, 48, 1950-1960.	1.3	6
113	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. Biology of Blood and Marrow Transplantation, 2007, 13, 497-499.	2.0	5
114	Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapy, 2007, 9, 348-355.	0.7	50
115	Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplantation, 2007, 40, 245-249.	2.4	46
116	Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplantation, 2007, 40, 273-277.	2.4	152
117	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. European Journal of Haematology, 2007, 78, 330-337.	2.2	25
118	Failure of CD34+ Mobilization in AML Patients Is Associated to an Abnormally High Chemosensitivity of Non Leukemic CFU-GM.. Blood, 2007, 110, 2849-2849.	1.4	0
119	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 2006, 107, 4177-4181.	1.4	158
120	The Use of Silicon Elastomer in Maxillofacial Rehabilitation as a Substitute for or in Conjunction With Resins. Journal of Craniofacial Surgery, 2006, 17, 152-162.	0.7	18
121	Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin's Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2006, 108, 3044-3044.	1.4	1
122	Adverse Events after Infusions of Cryopreserved Hematopoietic Stem Cells Depend on Non-Mononuclear Cell in Infused Suspension and on Patient Age.. Blood, 2006, 108, 5244-5244.	1.4	0
123	Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).. Blood, 2006, 108, 5236-5236.	1.4	0
124	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. Blood, 2006, 108, 3158-3158.	1.4	1
125	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica, 2006, 91, 837-9.	3.5	38
126	CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. Bone Marrow Transplantation, 2005, 35, 521-522.	2.4	8

#	ARTICLE	IF	CITATIONS
127	Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 131-134.	2.4	1
128	Acute Promyelocytic Leukemia during Pregnancy: Report of 3 Cases. International Journal of Hematology, 2004, 79, 31-36.	1.6	34
129	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leukemia Research, 2004, 28, 469-477.	0.8	57
130	G-CSF Alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplantation, 2003, 31, 747-754.	2.4	38
131	Alternation of Epirubicin and Mitoxantrone in CHOP-like Regimens Retains Efficacy and Reduces Overall Toxicity in Elderly Patients with High and Intermediate Grade Non-Hodgkin Lymphomas. Leukemia and Lymphoma, 2002, 43, 2319-2324.	1.3	6
132	Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes and Cancer, 2002, 33, 93-97.	2.8	92
133	Umbilical cord blood collection in Cesarean section: a comparison before and after placental delivery. Archives of Gynecology and Obstetrics, 2002, 266, 193-194.	1.7	2
134	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 774-780.	2.5	35
135	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. British Journal of Haematology, 2002, 117, 379-386.	2.5	123
136	Reasons to Eliminate Umbilical Cord Blood Units before Cryopreservation. Hematology, 2001, 6, 177-180.	1.5	0
137	Early Clamping of Umbilical Cord Blood and Foetal CD34 Enrichment. Vienna Clinical Weekly, 2001, 28, 141-144.	0.9	2
138	Testicular and cutaneous relapse after hematopoietic transplantation in a patient affected with APL. Bone Marrow Transplantation, 1999, 23, 751-751.	2.4	13
139	A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. European Journal of Haematology, 1996, 56, 7-11.	2.2	21
140	In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons. Leukemia and Lymphoma, 1995, 17, 449-453.	1.3	7
141	Early occurrence of a thyroid carcinoma in a patient who developed Graves' disease after treatment for Hodgkin's disease. Journal of Endocrinological Investigation, 1995, 18, 869-871.	3.3	4
142	Cutaneous vasculitis in non Hodgkin's lymphoma. Haematologica, 1995, 80, 529-31.	3.5	4
143	Unusual onset of severe varicella in adult immunocompromised patients. Annals of Hematology, 1992, 64, 155-156.	1.8	7
144	Trisomy 8 in philadelphia chromosome (ph1)-negative cells in the course of ph1-positive chronic myelocytic leukemia. Genes Chromosomes and Cancer, 1992, 4, 269-270.	2.8	27

#	ARTICLE	IF	CITATIONS
145	Inv(8)(p23q22) and recombinant derivative in a Sicilian family. Clinical Genetics, 1989, 36, 256-261.	2.0	6
146	A dermatoglyphic study of a group of Sicilian children with fragile-X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 177-183.	2.4	2
147	Low-Dose Cytarabine in Myelodysplastic Syndromes and Acute Leukemia. Acta Haematologica, 1986, 75, 125-126.	1.4	0
148	TREATMENT OF CML BLAST CRISIS WITH LOW DOSE ARA-C. British Journal of Haematology, 1985, 60, 773-774.	2.5	9
149	Immunomodulating Treatment in Patients with Aplastic Anemia. New England Journal of Medicine, 1983, 308, 1362-1363.	27.0	4
150	Stem Cell Transplantation in Acute Myeloid Leukemia. , 0, , .		0